Tilray medical supports new clinical trial to study medical cannabis in glioblastoma cancer treatment

Cantanhede, portugal, oct. 16, 2023 (globe newswire) -- tilray medical, a division of tilray brands, inc. ("tilray" or the "company") (nasdaq: tlry; tsx: tlry) and a global leader in medical cannabis, empowering the therapeutic alliance between patients and healthcare practitioners to make informed individualized health decisions, transforming healthcare, today announced their contribution to an independent clinical trial to research the efficacy of medical cannabis as a treatment for glioblastoma, a severe form of brain cancer. the clinical trial will be conducted in spain, recruiting 30 patients from eight specialized neuro-oncology medical sites, in partnership with renowned scientists from the spanish research group of neuro-oncology (geino) and the complutense university of madrid, with tilray medical providing the pharmaceutical-grade medical cannabis for the trial (thc/cbd 1:1) for administration to patients. the trial is funded by the medical cannabis bike tour foundation charity and is scheduled to commence at university hospital 12 de octubre, on september 5, 2023.
TLRY Ratings Summary
TLRY Quant Ranking